Key result
Lower serum miR-629-5p distinguishes ACS from stable chest pain and predicts adverse outcomes.
Why the study?
Non-invasive screening of ACS is a clinical challenge, leading investigators to evaluate the significance of miR-629-5p in ACS onset and development as a novel biomarker.
Does serum miR-629-5p level predict the onset, severity, and 1-year adverse outcomes in patients with acute coronary syndrome?
Population
115 ACS patients and 103 chest pain cases
Comparison
Serum miR-629-5p in ACS patients vs chest pain cases
Authors
Loading...
Should not change ACS practice; leaves open prospective validation of miR-629-5p as a biomarker.
Case-Control (n=218)
No
Does serum miR-629-5p level predict the onset, severity, and 1-year adverse outcomes in patients with acute coronary syndrome?
Serum miR-629-5p is a promising non-invasive biomarker for diagnosing acute coronary syndrome and predicting 1-year adverse outcomes, potentially by regulating MMP16-mediated myocardial injury.
Wang et al. (2026) conducted a case-control in Acute coronary syndrome (n=218). Serum miR-629-5p vs. Stable chest pain was evaluated on ACS onset and adverse outcomes (MACEs). Decreased serum miR-629-5p levels significantly discriminated acute coronary syndrome patients from those with stable chest pain and predicted adverse outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: